MGNX
MacroGenics, Inc.$3.02-0.03 (-0.82%)Prev Close$3.05·MCap$193.9M·P/E—·Vol326.6K·Yield—
▲
Buys (12M)
1
$150.5K
▼
Sells (12M)
5
$39.9K
◆
Net Activity
Net Buyer
$110.6K
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at MacroGenics, Inc. (MGNX) has been dominated by buying, with 1 insider purchase totaling $150.5K and 5 insider sales totaling $39.9K. The most recent insider transaction was by Bonvini Ezio (Sr VP, Research & CSO), who sold $11.0K worth of shares on Feb 12, 2026. MacroGenics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $193.9M.
MGNX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 6,433 | $1.71 | $11.0K | 0 |
| Feb 12, 2026 | Karrels James | SVP and CFO | Sell | 5,790 | $1.71 | $9.9K | 0 |
| Feb 12, 2026 | Peters Jeffrey Stuart | Senior VP, GC, and Secretary | Sell | 5,147 | $1.71 | $8.8K | 0 |
| Feb 12, 2026 | Smith Beth Ann | VP, Controller & Treasurer | Sell | 423 | $1.71 | $723.33 | 0 |
| Feb 12, 2026 | Spitznagel Thomas | Sr VP, Technical Ops | Sell | 5,520 | $1.71 | $9.4K | 0 |
| Aug 21, 2025 | HEIDEN WILLIAM K | Director | Buy | 100,000 | $1.51 | $150.5K | 111,000+909% |
| Feb 19, 2025 | Smith Beth Ann | VP, Controller & Treasurer | Sell | 423 | $2.56 | $1.1K | 9,532 |
| Apr 8, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 51,395 | $15.55 | $799.1K | 8,895-85% |
| Mar 8, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 19,625 | $21.50 | $421.9K | 8,895-69% |
| Mar 6, 2024 | Karrels James | SVP, CFO and Secretary | Sell | 30,000 | $20.50 | $615.0K | 171,452 |
| Mar 6, 2024 | Risser Eric Blasius | Chief Operating Officer | Sell | 41,159 | $19.76 | $813.5K | 65,059-39% |
| Mar 6, 2024 | Spitznagel Thomas | Sr VP, Technical Ops | Sell | 10,000 | $20.00 | $200.0K | 8,316-55% |
| Feb 28, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 16,124 | $17.22 | $277.7K | 8,895-64% |
| Feb 7, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 3,334 | $18.00 | $60.0K | 71,334 |
| Feb 7, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 76,251 | $16.50 | $1.26M | 21,875-78% |
| Feb 2, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 13,316 | $15.00 | $199.7K | 74,668 |
| Jan 22, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 13,316 | $12.00 | $159.8K | 87,984 |
| Dec 21, 2023 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 18,880 | $10.08 | $190.3K | 101,300 |
| Oct 4, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 150,000 | $4.46 | $669.6K | 9,929,963 |
| Sep 11, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $5.26 | $1.05M | 9,779,963 |
| Sep 1, 2023 | HURWITZ EDWARD | Director | Buy | 15,000 | $4.91 | $73.7K | 33,074+83% |
| Mar 14, 2023 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 5,372 | $6.03 | $32.4K | 0Exit |
| Feb 16, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 500,000 | $5.07 | $2.53M0.8% OS | 9,579,963 |
| Jan 23, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 150,000 | $5.30 | $794.9K | 9,079,963 |
| Dec 28, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 400,000 | $5.75 | $2.30M0.6% OS | 8,929,963 |
| Nov 25, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 300,000 | $5.96 | $1.79M | 8,529,963 |
| Oct 25, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 500,000 | $4.50 | $2.25M0.8% OS | 8,229,963 |
| Oct 21, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 454,399 | $3.89 | $1.77M0.7% OS | 7,729,963 |
| Jun 17, 2022 | Karrels James | SVP, CFO and Secretary | Buy | 40,000 | $2.47 | $98.8K | 191,776+26% |
| Nov 23, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $18.50 | $3.70M | 7,275,564 |
| Sep 30, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $20.56 | $4.11M | 7,075,564 |
| Sep 20, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 600,000 | $20.61 | $12.36M0.9% OS | 6,875,564 |
| Jul 20, 2021 | Spitznagel Thomas | Sr VP, BPD & Manufacturing | Sell | 5,000 | $25.01 | $125.0K | 0Exit |
| Jun 23, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 75,000 | $21.74 | $1.63M | 6,275,564 |
| Jun 17, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 175,000 | $20.82 | $3.64M | 6,200,564 |
| Apr 19, 2021 | Spitznagel Thomas | Sr VP, BPD & Manufacturing | Sell | 5,000 | $30.91 | $154.6K | 0Exit |
| Mar 24, 2021 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 3,917 | $32.00 | $125.3K | 79,890 |
| Mar 24, 2021 | Karrels James | SVP, CFO and Secretary | Sell | 15,000 | $33.00 | $495.0K | 143,460 |
| Mar 9, 2021 | Peters Jeffrey Stuart | General Counsel | Sell | 21,749 | $26.50 | $576.3K | 0Exit |
MGNX Insider Buying Activity
The following table shows recent insider purchases of MacroGenics, Inc. (MGNX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 21, 2025 | HEIDEN WILLIAM K | Director | Buy | 100,000 | $1.51 | $150.5K | 111,000+909% |
| Oct 4, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 150,000 | $4.46 | $669.6K | 9,929,963 |
| Sep 11, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $5.26 | $1.05M | 9,779,963 |
| Sep 1, 2023 | HURWITZ EDWARD | Director | Buy | 15,000 | $4.91 | $73.7K | 33,074+83% |
| Feb 16, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 500,000 | $5.07 | $2.53M0.8% OS | 9,579,963 |
| Jan 23, 2023 | BIOTECH TARGET N V | 10% Owner | Buy | 150,000 | $5.30 | $794.9K | 9,079,963 |
| Dec 28, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 400,000 | $5.75 | $2.30M0.6% OS | 8,929,963 |
| Nov 25, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 300,000 | $5.96 | $1.79M | 8,529,963 |
| Oct 25, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 500,000 | $4.50 | $2.25M0.8% OS | 8,229,963 |
| Oct 21, 2022 | BIOTECH TARGET N V | 10% Owner | Buy | 454,399 | $3.89 | $1.77M0.7% OS | 7,729,963 |
| Jun 17, 2022 | Karrels James | SVP, CFO and Secretary | Buy | 40,000 | $2.47 | $98.8K | 191,776+26% |
| Nov 23, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $18.50 | $3.70M | 7,275,564 |
| Sep 30, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 200,000 | $20.56 | $4.11M | 7,075,564 |
| Sep 20, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 600,000 | $20.61 | $12.36M0.9% OS | 6,875,564 |
| Jun 23, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 75,000 | $21.74 | $1.63M | 6,275,564 |
| Jun 17, 2021 | BIOTECH TARGET N V | 10% Owner | Buy | 175,000 | $20.82 | $3.64M | 6,200,564 |
MGNX Insider Selling Activity
The following table shows recent insider sales of MacroGenics, Inc. (MGNX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 6,433 | $1.71 | $11.0K | 0 |
| Feb 12, 2026 | Karrels James | SVP and CFO | Sell | 5,790 | $1.71 | $9.9K | 0 |
| Feb 12, 2026 | Peters Jeffrey Stuart | Senior VP, GC, and Secretary | Sell | 5,147 | $1.71 | $8.8K | 0 |
| Feb 12, 2026 | Smith Beth Ann | VP, Controller & Treasurer | Sell | 423 | $1.71 | $723.33 | 0 |
| Feb 12, 2026 | Spitznagel Thomas | Sr VP, Technical Ops | Sell | 5,520 | $1.71 | $9.4K | 0 |
| Feb 19, 2025 | Smith Beth Ann | VP, Controller & Treasurer | Sell | 423 | $2.56 | $1.1K | 9,532 |
| Apr 8, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 51,395 | $15.55 | $799.1K | 8,895-85% |
| Mar 8, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 19,625 | $21.50 | $421.9K | 8,895-69% |
| Mar 6, 2024 | Karrels James | SVP, CFO and Secretary | Sell | 30,000 | $20.50 | $615.0K | 171,452 |
| Mar 6, 2024 | Risser Eric Blasius | Chief Operating Officer | Sell | 41,159 | $19.76 | $813.5K | 65,059-39% |
| Mar 6, 2024 | Spitznagel Thomas | Sr VP, Technical Ops | Sell | 10,000 | $20.00 | $200.0K | 8,316-55% |
| Feb 28, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 16,124 | $17.22 | $277.7K | 8,895-64% |
| Feb 7, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 3,334 | $18.00 | $60.0K | 71,334 |
| Feb 7, 2024 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 76,251 | $16.50 | $1.26M | 21,875-78% |
| Feb 2, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 13,316 | $15.00 | $199.7K | 74,668 |
| Jan 22, 2024 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 13,316 | $12.00 | $159.8K | 87,984 |
| Dec 21, 2023 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 18,880 | $10.08 | $190.3K | 101,300 |
| Mar 14, 2023 | Peters Jeffrey Stuart | Senior VP and General Counsel | Sell | 5,372 | $6.03 | $32.4K | 0Exit |
| Jul 20, 2021 | Spitznagel Thomas | Sr VP, BPD & Manufacturing | Sell | 5,000 | $25.01 | $125.0K | 0Exit |
| Apr 19, 2021 | Spitznagel Thomas | Sr VP, BPD & Manufacturing | Sell | 5,000 | $30.91 | $154.6K | 0Exit |
| Mar 24, 2021 | Bonvini Ezio | Sr VP, Research & CSO | Sell | 3,917 | $32.00 | $125.3K | 79,890 |
| Mar 24, 2021 | Karrels James | SVP, CFO and Secretary | Sell | 15,000 | $33.00 | $495.0K | 143,460 |
| Mar 9, 2021 | Peters Jeffrey Stuart | General Counsel | Sell | 21,749 | $26.50 | $576.3K | 0Exit |
MGNX Insiders
Similar Stocks to MGNX
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B